Evidence map›Paper›PMID 40135861›Full record

ArticleAntimicrobial agents and chemotherapy2025

Mathilde Lacroix, Jérémy Moreau, Claudia Zampaloni, Caterina Bissantz, Hélène Mirfendereski, Hamasseh Shirvani, Sandrine Marchand, William Couet, Alexia Chauzy

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mathilde LacroixUniversité de Poitiers INSERM, PHAR2, Poitiers, Nouvelle-Aquitaine, France.
Jérémy MoreauUniversité de Poitiers INSERM, PHAR2, Poitiers, Nouvelle-Aquitaine, France.
Claudia ZampaloniRoche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Basel, Basel-Stadt, Switzerland.
Caterina BissantzRoche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Basel-Stadt, Switzerland.
Hélène MirfendereskiDépartement de Pharmacocinétique et Toxicologie, CHU Poitiers, Poitiers, Nouvelle-Aquitaine, France.
Hamasseh ShirvaniInstitut Roche-Boulogne-Billancourt, Boulogne-Billancourt, France.
Sandrine MarchandUniversité de Poitiers INSERM, PHAR2, Poitiers, Nouvelle-Aquitaine, France.ORCID 0000-0001-5279-6678
William CouetUniversité de Poitiers INSERM, PHAR2, Poitiers, Nouvelle-Aquitaine, France.ORCID 0000-0002-7116-8965
Alexia ChauzyUniversité de Poitiers INSERM, PHAR2, Poitiers, Nouvelle-Aquitaine, France.ORCID 0000-0001-6443-5888

Funding

Association Nationale de la Recherche et de la TechnologieRoche
6 · The paper itself

Abstract

The antibacterial efficacy of polymyxins in lungs may be impacted by mucin. The aim of this study was to characterize

Indexed as

Acinetobacter baumanniiAnti-Bacterial AgentsMucinsPolymyxin BAcinetobacter InfectionsColistinDrug Resistance, Multiple, BacterialHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsColistinMucinsPolymyxin BA. baumanniimucinpolymyxin Bsemi-mechanistic PK/PD modeling

Identifiers

PMID40135861
PMCPMC12057341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.